Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2021. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
| Capital Metric | Value as of 31 May 2021 |
|---|---|
| Issued Ordinary Shares | 5,386,708,271 (25 pence each) |
| Treasury Shares | 355,205,950 |
| Total Voting Rights | 5,031,502,321 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document reports a static snapshot of share capital as of 31 May 2021 without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures beyond the regulatory requirement to notify shareholders of the voting rights denominator.
Investor Verification Checklist
- Verify the total number of voting rights (5,031,502,321) for calculating disclosure thresholds under FCA rules.
- Confirm the number of shares held in Treasury (355,205,950) to understand the difference between issued capital and voting capital.
- Note that this filing does not contain financial performance results; refer to Form 20-F or quarterly reports for revenue and profit data.